These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 14501869

  • 1. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients.
    Kuzuya T, Kobayashi T, Moriyama N, Nagasaka T, Yokoyama I, Uchida K, Nakao A, Nabeshima T.
    Transplantation; 2003 Sep 15; 76(5):865-8. PubMed ID: 14501869
    [Abstract] [Full Text] [Related]

  • 2. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
    Azarpira N, Aghdaie MH, Behzad-Behbahanie A, Geramizadeh B, Behzadi S, Malekhoseinie SA, Raisjalal GH, Rahsaz M, Pourgholami A, Sagheb F.
    Exp Clin Transplant; 2006 Jun 15; 4(1):416-9. PubMed ID: 16827636
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients.
    Foote CJ, Greer W, Kiberd B, Fraser A, Lawen J, Nashan B, Belitsky P.
    Transplantation; 2007 May 27; 83(10):1380-4. PubMed ID: 17519790
    [Abstract] [Full Text] [Related]

  • 6. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS.
    Clin Transplant; 2005 Oct 27; 19(5):638-43. PubMed ID: 16146556
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato T, Habuchi T.
    Transplant Proc; 2005 May 27; 37(4):1730-2. PubMed ID: 15919447
    [Abstract] [Full Text] [Related]

  • 9. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
    Bunnag S, Vareesangthip K, Ong-ajyooth L.
    J Med Assoc Thai; 2006 Aug 27; 89 Suppl 2():S228-34. PubMed ID: 17044476
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
    Irtan S, Saint-Marcoux F, Rousseau A, Zhang D, Leroy V, Marquet P, Jacqz-Aigrain E.
    Ther Drug Monit; 2007 Feb 27; 29(1):96-102. PubMed ID: 17304156
    [Abstract] [Full Text] [Related]

  • 12. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
    Mendes J, Martinho A, Simoes O, Mota A, Breitenfeld L, Pais L.
    Transplant Proc; 2009 Apr 27; 41(3):840-2. PubMed ID: 19376366
    [Abstract] [Full Text] [Related]

  • 13. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients.
    Falck P, Asberg A, Guldseth H, Bremer S, Akhlaghi F, Reubsaet JL, Pfeffer P, Hartmann A, Midtvedt K.
    Transplantation; 2008 Jan 27; 85(2):179-84. PubMed ID: 18212621
    [Abstract] [Full Text] [Related]

  • 14. Effects of cyclosporine a on single-dose pharmacokinetics of intravenous itraconazole in patients with hematologic malignancies.
    Timmers GJ, Kessels LW, Wilhelm AJ, Veldkamp AI, Bosch TM, Beijnen JH, Huijgens PC.
    Ther Drug Monit; 2008 Jun 27; 30(3):301-5. PubMed ID: 18520601
    [Abstract] [Full Text] [Related]

  • 15. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
    Aros CA, Schneider HO, Flores CA, Ardiles LG, Alruiz PA, Jerez V, Mezzano SA.
    Transplant Proc; 2005 Apr 27; 37(3):1580-2. PubMed ID: 15866679
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M, Crespo M, Millán O, Serón D, Torregrosa V, Jiménez O, Moreso F, Martorell J, Grinyo JM, Oppenheimer F.
    Transplant Proc; 2007 Sep 27; 39(7):2160-2. PubMed ID: 17889124
    [Abstract] [Full Text] [Related]

  • 18. Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring.
    Ray JE, Keogh AM, McLachlan AJ.
    J Heart Lung Transplant; 2006 Oct 27; 25(10):1223-9. PubMed ID: 17045935
    [Abstract] [Full Text] [Related]

  • 19. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
    Larsen UL, Hyldahl Olesen L, Guldborg Nyvold C, Eriksen J, Jakobsen P, Østergaard M, Autrup H, Andersen V.
    Scand J Clin Lab Invest; 2007 Oct 27; 67(2):123-34. PubMed ID: 17365992
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.